Overview
- Description
The company is developing next-generation antibiotics based on antimicrobial peptides to combat multi-drug-resistant bacterial infections, with its lead candidate OMN6 targeting gram-negative bacteria and backed by patents in the EU and US.
- Website
- Country
- Israel
- Sector
- Health Biotechnology
*By clicking here you will be leaving the official EIC website and you will be directed to the Dealroom.co domain, an official EISMEA contractor for the EIC investor matchmaking platform.